Dr. Chris Varma is a successful entrepreneur and investor in the life sciences industry. In May 2013, Dr. Varma cofounded Vision Medicines, Inc., an orphan ophthalmology company, and serves as its president and chief executive officer. In 2010, he co-founded Blueprint Medicines, a leading oncology therapeutics company located in Cambridge, MA and served as its president, chief executive officer, and director from its founding, where he raised $40M in a Series-A financing and oversaw the building of the scientific platform and therapeutic pipeline that is now in clinical testing.

Previously at Third Rock Ventures as an entrepreneur-in-residence, Dr. Varma co-founded Warp Drive Bio, which executed a $125M strategic partnership with Sanofi. Prior to Third Rock Ventures, he was a partner at Flagship Ventures focusing on 3 life science investments such as Tetraphase Pharmaceuticals (Nasdaq: TTPH) as well as investment opportunities in oncology. Before joining Flagship, he oversaw efforts spanning business development, strategy, and sales and marketing at Novartis AG.

Dr. Varma holds a Ph.D. in Biomedical Sciences from the Harvard-MIT Program in Health Sciences & Technology (HST), a M.S. in Management from Stanford University, and a M.S. and a B.S. in Computer Science from Stanford University. Dr. Varma serves as a member of the Harvard Medical School (HMS) Therapeutics Advisory Council and the HMS Discovery Council, as well as a leadership board member of The McGovern Institute for Brain Research at MIT.